Abstract:Xeroderma pigmentosum (XP) is caused by defects in the nucleotide excision repair (NER) pathway. NER removes helix-distorting DNA lesions, such as UV-induced photodimers, from the genome. Patients suffering from XP exhibit exquisite sun sensitivity, high incidence of skin cancer, and in some cases neurodegeneration. The severity of XP varies tremendously depending upon which NER gene is mutated and how severely the mutation affects DNA repair capacity. XPF-ERCC1 is a structure-specific endonuclease essential for incising the damaged strand of DNA in NER. Missense mutations in XPF can result not only in XP, but also XPF-ERCC1 (XFE) progeroid syndrome, a disease of accelerated aging. In an attempt to determine how mutations in XPF can lead to such diverse symptoms, the effects of a progeria-causing mutation (XPF(R153P)) were compared to an XP-causing mutation (XPF(R799W)) in vitro and in vivo. Recombinant XPF harboring either mutation was purified in a complex with ERCC1 and tested for its ability to incise a stem-loop structure in vitro. Both mutant complexes nicked the substrate indicating that neither mutation obviates catalytic activity of the nuclease. Surprisingly, differential immunostaining and fractionation of cells from an XFE progeroid patient revealed that XPF-ERCC1 is abundant in the cytoplasm. This was confirmed by fluorescent detection of XPF(R153P)-YFP expressed in Xpf mutant cells. In addition, microinjection of XPF(R153P)-ERCC1 into the nucleus of XPF-deficient human cells restored nucleotide excision repair of UV-induced DNA damage. Intriguingly, in all XPF mutant cell lines examined, XPF-ERCC1 was detected in the cytoplasm of a fraction of cells. This demonstrates that at least part of the DNA repair defect and symptoms associated with mutations in XPF are due to mislocalization of XPF-ERCC1 into the cytoplasm of cells, likely due to protein misfolding. Analysis of these patient cells therefore reveals a novel mechanism to potentially regulate a cell's capacity for DNA repair: by manipulating nuclear localization of XPF-ERCC1.

Synthetic rescue of Xeroderma Pigmentosum C phenotype via PIK3C3 downregulation

Isoconazole and Clemizole Hydrochloride Partially Reverse the Xeroderma Pigmentosum C Phenotype

Generation and characterization of CRISPR-Cas9-Mediated Gene Knockout in Human Skin Cells

Xeroderma Pigmentosum C: A Valuable Tool to Decipher the Signaling Pathways in Skin Cancers

In Silico Drug Repurposing by Structural Alteration after Induced Fit: Discovery of a Candidate Agent for Recovery of Nucleotide Excision Repair in Xeroderma Pigmentosum Group D Mutant (R683W)

XPC beyond nucleotide excision repair and skin cancers

Revealing the UV response of melanocytes in xeroderma pigmentosum group A using patient-derived induced pluripotent stem cells

Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies

Successful Treatment of Non-Melanoma Skin Cancer in Three Patients with Xeroderma Pigmentosum by Modified ALA-PDT.

Phosphorylation Of Xeroderma Pigmentosum Group C Regulates Ultraviolet-Induced Dna Damage Repair

Identification of Four Novel XPC Mutations in Two Xeroderma Pigmentosum Complementation Group C Patients and Functional Study of XPC Q320X Mutant.

Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient

Functional retroviral vector for gene therapy of xeroderma pigmentosum group D patients

Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients

Xeroderma Pigmentosum: General Aspects and Management

Novel therapeutic approaches to xeroderma pigmentosum

491 Identification of Four Novel XPC Mutations in Two Xeroderma Pigmentosum Complementation Group C Patients and Functional Study of XPC Q320X Mutant

Gene transduction in skin cells: preventing cancer in xeroderma pigmentosum mice

Use of a Topical Film-Forming Medical Device Containing Repairsomes® in a Patient with Xeroderma Pigmentosum to Avoid Progression to Skin Cancerization

XPC initiation codon mutation in xeroderma pigmentosum patients with and without neurological symptoms

Xeroderma pigmentosum--bridging a gap between clinic and laboratory